The UK Will Spend $13.9 Million On a Puberty Blocker Study—But to What End?

I report on the reactions from experts and skeptics to the British health authority's plan to study the use of puberty blockers to treat gender-related distress in minors.

My latest

I’ve got an article out in The New York Sun today about the British National Health Service’s announcement that it will spend $13.9 million on a forthcoming study of puberty blockers in gender-distressed minors. This Substack is an appendix to that article (which you can read by clicking here), because I wanted to put out there in the public record the full details of many of the responses I received from experts in and skeptics of the field of pediatric gender medicine.

Note that I reached out to a long list of advocates of this medical field, but only heard back from one (silence from these folks is typical where my outreach is concerned): Helen Webberley, the controversial head of Gender GP. This is a telehealth company that prescribes gender-transition drugs to British minors from overseas.

First, I highly recommend the video below of a recent panel discussion in London about the pediatric gender medicine, the Cass Review (Britain’s comprehensive review of pediatric gender …